We highlight cancer-specific down regulation of NRP-1, SNAI1 and SEMA4A in PBMCs with a further decrease of SNAI1, SEMA4A, VEGFR3 and PLXNA1 in patients with advanced disease. Here, FLT4 is linked to cancer.